Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    16611412 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Durvalumab
2 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011

Indicates status has not been verified in more than two years